New drug shows promise in keeping advanced ovarian cancer at bay

NCT ID NCT02655016

Ongoing Disease control Sponsor: Tesaro, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested whether taking the drug niraparib as ongoing 'maintenance' therapy could help keep advanced ovarian cancer from returning after successful initial chemotherapy. It involved 733 women with Stage III or IV ovarian cancer who had responded well to their first round of platinum-based chemotherapy. Participants were randomly assigned to receive either niraparib or a placebo pill to see if the drug could extend the time before the cancer progressed again.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Tempe, Arizona, 85284, United States
GSK Investigational Site

Tucson, Arizona, 85710, United States
GSK Investigational Site

Tucson, Arizona, 85724, United States
GSK Investigational Site

San Francisco, California, 94115, United States
GSK Investigational Site

San Francisco, California, 94118, United States
GSK Investigational Site

Santa Rosa, California, 95403, United States
GSK Investigational Site

New Haven, Connecticut, 06510, United States
GSK Investigational Site

Jacksonville, Florida, 32224, United States
GSK Investigational Site

Miami, Florida, 33136, United States
GSK Investigational Site

Atlanta, Georgia, 30342, United States
GSK Investigational Site

Savannah, Georgia, 31404, United States
GSK Investigational Site

Geneva, Illinois, 60555, United States
GSK Investigational Site

Indianapolis, Indiana, 46237, United States
GSK Investigational Site

Indianapolis, Indiana, 46260, United States
GSK Investigational Site

Iowa City, Iowa, 52242, United States
GSK Investigational Site

Covington, Louisiana, 70433, United States
GSK Investigational Site

New Orleans, Louisiana, 70121, United States
GSK Investigational Site

Baltimore, Maryland, 21215-5271, United States
GSK Investigational Site

Rockville, Maryland, 20910, United States
GSK Investigational Site

Burlington, Massachusetts, 01805, United States
GSK Investigational Site

Grand Rapids, Michigan, 49503, United States
GSK Investigational Site

Minneapolis, Minnesota, 55433, United States
GSK Investigational Site

Springfield, Missouri, 97477, United States
GSK Investigational Site

Neptune City, New Jersey, 07753, United States
GSK Investigational Site

Harrison, New York, 10604, United States
GSK Investigational Site

Mineola, New York, 11501, United States
GSK Investigational Site

New York, New York, 10016, United States
GSK Investigational Site

Rochester, New York, 14620, United States
GSK Investigational Site

Chapel Hill, North Carolina, 27599-7570, United States
GSK Investigational Site

Wilmington, North Carolina, 28401, United States
GSK Investigational Site

Columbus, Ohio, 43210, United States
GSK Investigational Site

Oklahoma City, Oklahoma, 73104, United States
GSK Investigational Site

Tulsa, Oklahoma, 74146, United States
GSK Investigational Site

Portland, Oregon, 97210, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Willow Grove, Pennsylvania, 19090, United States
GSK Investigational Site

Providence, Rhode Island, 02905, United States
GSK Investigational Site

Charleston, South Carolina, 29425, United States
GSK Investigational Site

Sioux Falls, South Dakota, 57105, United States
GSK Investigational Site

Fort Worth, Texas, 76104, United States
GSK Investigational Site

The Woodlands, Texas, 77380, United States
GSK Investigational Site

Tyler, Texas, 75701, United States
GSK Investigational Site

Salt Lake City, Utah, 84112, United States
GSK Investigational Site

Kennewick, Washington, 99336, United States
GSK Investigational Site

Seattle, Washington, 98104, United States
GSK Investigational Site

Spokane, Washington, 99202, United States
GSK Investigational Site

Milwaukee, Wisconsin, 53226, United States
GSK Investigational Site

Bonheiden, 2820, Belgium
GSK Investigational Site

Brussels, 1000, Belgium
GSK Investigational Site

Brussels, 1200, Belgium
GSK Investigational Site

Ghent, 9000, Belgium
GSK Investigational Site

Hasselt, 3500, Belgium
GSK Investigational Site

Leuven, 3000, Belgium
GSK Investigational Site

Libramont, 6800, Belgium
GSK Investigational Site

Namur, 5000, Belgium
GSK Investigational Site

Aalborg, 9000, Denmark
GSK Investigational Site

Copenhagen, 2100, Denmark
GSK Investigational Site

Herlev, 2730, Denmark
GSK Investigational Site

Odense C, 5000, Denmark
GSK Investigational Site

Kuopio, 70210, Finland
GSK Investigational Site

Oulu, 90029, Finland
GSK Investigational Site

Tampere, 33521, Finland
GSK Investigational Site

Turku, 20520, Finland
GSK Investigational Site

Angers, 49000, France
GSK Investigational Site

Aachen, 52074, Germany
GSK Investigational Site

Berlin, 13353, Germany
GSK Investigational Site

Essen, 45136, Germany
GSK Investigational Site

Fürth, 90766, Germany
GSK Investigational Site

Göttingen, 37075, Germany
GSK Investigational Site

Heidelberg, 69120, Germany
GSK Investigational Site

Hildesheim, 31134, Germany
GSK Investigational Site

Mannheim, 68167, Germany
GSK Investigational Site

München, 81377, Germany
GSK Investigational Site

Dublin, 8, Ireland
GSK Investigational Site

Dunmore RoadWaterford, Ireland
GSK Investigational Site

Galway, H91 YR71, Ireland
GSK Investigational Site

Haifa, 38100, Israel
GSK Investigational Site

Ramat Gan, 52621, Israel
GSK Investigational Site

Tel Aviv, 64239, Israel
GSK Investigational Site

Lecce, 73100, Italy
GSK Investigational Site

Milan, 20132, Italy
GSK Investigational Site

Milan, 20133, Italy
GSK Investigational Site

Modena, 41100, Italy
GSK Investigational Site

Naples, 80131, Italy
GSK Investigational Site

Oslo, 0310, Norway
GSK Investigational Site

Badalona, 08916, Spain
GSK Investigational Site

Barcelona, 08003, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Barcelona, 8035, Spain
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

Donostia / San Sebastian, 20014, Spain
GSK Investigational Site

Elche Alicante, 03203, Spain
GSK Investigational Site

Girona, 17007, Spain
GSK Investigational Site

Madrid, 28033, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Seville, 41014, Spain
GSK Investigational Site

Valencia, 46009, Spain
GSK Investigational Site

Valencia, 46010, Spain
GSK Investigational Site

Zaragoza, 50009, Spain
GSK Investigational Site

Stockholm, SE-171 76, Sweden
GSK Investigational Site

Uppsala, SE-751 85, Sweden
GSK Investigational Site

Basel, 4031, Switzerland
GSK Investigational Site

Bern, 3010, Switzerland
GSK Investigational Site

Frauenfeld, 8501, Switzerland
GSK Investigational Site

Zurich, 8091, Switzerland
GSK Investigational Site

Blackburn, BB2 3HH, United Kingdom
GSK Investigational Site

Edinburgh, G12 0YN, United Kingdom
GSK Investigational Site

Exeter, EX2 5DW, United Kingdom
GSK Investigational Site

Glasgow, G12 0YN, United Kingdom
GSK Investigational Site

London, W12 0HS, United Kingdom
GSK Investigational Site

Portsmouth, PO6 3LY, United Kingdom
GSK Investigational Site

Sheffield, S10 2SJ, United Kingdom
GSK Investigational Site

Truro, TR1 3LJ, United Kingdom

Conditions

Explore the condition pages connected to this study.

OVARIAN NEOPLASMS